Sutro Biopharma, Inc. - Common Stock (STRO)

Last Price0.6024

Change+0.0304 (5.31%)

NASDAQ · Last Trade: Apr 12th, 7:06 AM EDT

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise --

By Vaxcyte, Inc. · Via GlobeNewswire · November 27, 2023

Why Investors Are Suddenly Excited About Vaxcyte

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

Via MarketBeat · October 31, 2022